![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Brecita (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: Brecita
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Positive topline results from a Phase 3 study investigating the efficacy and safety of adjunctive brivaracetam in participants across Asia (≥16 to 80 years of age) with partial seizures with or without secondary generalization.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: Brecita
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
BRIVIACT (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: Briviact
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
With these positive CHMP opinions, BRIVIACT® (brivaracetam) and VIMPAT® (lacosamide) will provide young patients and their caregivers with additional treatment options for POS with or without secondary generalization.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: Briviact
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2022
Details:
Brivaracetam Tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Natco Pharma has launched Brivaracetam tablets under brand BRECITA in India. Brivaracetam, indicated towards the treatment of epilepsy, is developed by UCB Pharma and currently marketed in India by Dr Reddy's under the brand name Briviact.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: Brecita
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
15 scientific presentations highlight data on BRIVACT® (brivaracetam) CV, NAYZILAM® (midazolam) nasal spray CIV, VIMPAT® (lacosamide) CV, and others, illustrating UCB's commitment to developing new treatment options for patients in their treatment journey.
Lead Product(s): Brivaracetam
Therapeutic Area: Neurology Product Name: BRIVACT
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020